Kidney health awareness to be raised during World Kidney Day and Australia’s Kidney Health Week

Melbourne, Australia, 11 March 2021: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. Today kidney health awareness becomes a focus globally during World Kidney Day. This awareness day precedes Australia’s Kidney Health Week which takes place 15-21 March 2021. OccuRx, is proud to increase global […]

OccuRx joins 39th Annual J.P. Morgan Healthcare Conference virtually

Melbourne, Australia, 09 January 2021: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, are pleased to announce its management team including Executive Chairman, Professor Darren Kelly, will join J.P. Morgan Healthcare Conference virtually from 11th 14th January 2021. “We’re excited to attend this year’s virtual […]

OccuRx initiates the MAD Phase I Study for lead candidate OCX063

Melbourne, Australia, 05 May 2020: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases today announces the initiation of the multiple ascending dose (MAD) phase for its lead candidate OCX-063. Following the successful progress of the SAD portion of the Phase I study being conducted at […]

OccuRx presents new research at ARVO

Melbourne, Australia, 03 May 2020: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, is pleased to announce they will be presenting at the Association for Research in Vision and Ophthalmology (ARVO). OccuRx will present new research titled ‘Oral delivery of the anti-fibrotic, FT011, achieves safe […]

OccuRx presents new research at ARVO Annual Meeting

Melbourne, Australia, 03 May 2020: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases is pleased to announce that we will be presenting an oral presentation at the Association for Research in Vision and Ophthalmology (ARVO) 3rd – 7th May 2020. The company will present two […]

First healthy volunteer dosed in OccuRx’s Phase I clinical trial

Melbourne, Australia, 22 January 2020: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, is pleased to announce the first healthy volunteer has been dosed as part of its Phase I single ascending dose study. The Phase I trial is being conducted at Nucleus Network in […]

OccuRx attending 38th Annual J.P. Morgan Healthcare Conference in San Francisco to highlight its scientific advancements

Melbourne, Australia, 07 January 2020: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, are pleased to announce the attendance of the senior management team including Chief Executive Officer, Professor Darren Kelly at the 38th J.P. Morgan Healthcare Conference. The conference will be held between 13th – […]

OccuRx commences Phase I clinical trial for lead candidate molecule OCX-063

Melbourne, Australia, 18 December 2019: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, today announced the commencement of their Phase I clinical trial for the new compound OCX-063. The Phase I study will be a randomized, double blind, placebo-controlled, dose-escalating study of the safety, tolerability, […]

In conversation with Darren Kelly, CEO of Certa Therapeutics and OccuRx – Fierce Biotech

Melbourne, Australia, 26 November 2019, written by Amirah Al Idrus: At first glance, Darren Kelly doesn’t seem to sleep. He’s the CEO of not one but two fibrosis-related biotechs, an entrepreneur in residence at Brandon Capital, Australia’s largest life sciences-focused VC firm, a director at the Centre for Eye Research Australia and—to top it all […]

OccuRx team to meet with biotech industry leaders during BIO conference in Philadelphia

Melbourne, Australia, 03 June 2019: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. This year’s Biotechnology Innovation Organisation (BIO) International Convention will be attended by OccuRx and its management team including Chief Executive Officer, Professor Darren Kelly.  The BIO convention is set to take place in […]